EUCTR2019-003864-27-FI进行中（未招募）1 期
Effect of inhalation formulation on uncontrolled asthma - EFFIE
HUS / Mika Mäkelä0 个研究点目标入组 70 人开始时间: 2019年10月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •age 12-<18 years (male and female)
- •prior doctor diagnosed asthma with need of regular anti-asthmatic medication for at least 3 months; except Relvar® Ellipta® and Flutiform® K-haler®, and insufficient asthma control
- •FEV1/FVC reduced (z<-1,65 SD )
- •signed informed consent
- •sufficient skills to communicate in Finnish
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 70
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •other pulmonary disease than asthma
- •active and uncontrolled cardiovascular or other systemic disease
研究者
相似试验
已完成
3 期
Evaluation of the effect of nano-based inhalation solution to relieve shortness of breath in COVID-19 patientsIRCT20190226042851N1Ahvaz University of Medical Sciences40
进行中（未招募）
1 期
The inhaled combination of budesonide-formoterol consists a basic asthma treatment.A helpful specific index for the prognosis of future exacerbation risk and deterioration of lung function,is the Exhaled Nitric Oxide.The objective of the current study is the evaluation of Pulmoton- Elpenhaler in Exhaled Nitric Oxide of patients with bronchial asthma.Bronchial AsthmaEUCTR2014-001029-34-GRELPEN Pharmaceutical Co. Inc
已完成
不适用
What is the effect of inhalational anaesthetic agents on blood glucose levels in non diabetic patients?CTRI/2021/12/038579All India Institute of Medical Sciences Raipur105
进行中（未招募）
不适用
Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 versus Placebo on the HPA Axis of Adolescent and Adult AsthmaticsAsthmaMedDRA version: 12.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2009-017669-44-DEGlaxoSmithKline Research & Development Ltd185
进行中（未招募）
2 期
An investigation into how adding an inhaled steroid to COPD treatment may potentially protect against heart disease.Chronic Obstructive Airways Disease [COPD]RespiratoryISRCTN29148209Hull University Teaching Hospitals NHS Trust40